

Note: Trials are first grouped together by Country Each trial description also lists the treatment stage under the "Stage" heading. Trials that are specifically for GIST are listed first. Trials are then sorted by phase in descending order and then by drug name. See the US trial listing for trials in the United States.

Argentina

Nilotinib or Imatinib

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00751036**
 Contact: Novartis US: 1-800-340-6843

Site name unknown
Buenos Aires
 Buenos Aires, Argentina

Australia

Imatinib, Nilotinib

REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response

Phase: 2
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #:
 Contact: Karen Bracken
 02 9562 5071
 registerstudy@ctc.usyd.edu.au
 karen.bracken@ctc.usyd.edu.au

Canberra Hospital
 Garran, ACT Australia
 Desmond Yip, MD

Sydney Haematology and Oncology Clinics
 Hornsby, NSW Australia
 Gavin Marx, MD

Prince of Wales Hospital
 Randwick, NSW Australia
 David Goldstein, MD

The Tweed Hospital
 Tweed Heads, NSW Australia
 Prof. Ehtesham Abdi

Calvary Mater Newcastle
 Waratah, NSW Australia
 Tony Bonaventura, MD

Princess Alexandra Hospital
 Woolloongabba, Queensland Australia
 Euan Walpole, MD

Ashford Cancer Center
 Ashford, SA Australia
 Sara McLaughlin
 +08 8351 0211
 Dusan Kotasek, MD

Flinders Medical Center
 Bedford Park, SA Australia
 Alison Richards
 +08 8204 4830
 Chris Karapetis, MD

Royal Hobart Hospital
 Hobart, Tasmania Australia
 Ian Byard, MD

Royal Melbourne Hospital
 Parkville, Vic Australia
 Jayesh desai, MD

Box Hill Hospital
 Box Hill, Victoria Australia
 Prasad Cooray, MD

Peter McCallum Cancer Institute
 East Melbourne, Victoria Australia
 10 St Andrews Pl, East Melbourne, VIC 3002, Australia
 Jayesh Desai, MD

Border Medical Oncology
 Wodonga, Victoria Australia
 Craig Underhill, MD

BMS-754807

*Multiple Dose Study In Cancer Patients:
Safety and Tolerability of BMS-754807 in
Advanced or Metastatic Solid Tumors*

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00569036**
 Contact: For site information outside the USA please email:
 Clinical.Trials@bms.com
 First line of email MUST contain NCT# & Site#.

Site name unknown, East Melbourne
 East Melbourne, Australia
 Site # 003

Site name unknown, Footscray, Australia
 Footscray, Victoria
 Australia
 Site # 004

Site name unknown, Heidelberg Australia
 Heidelberg, Victoria
 Australia
 Site # 002

Site name unknown, Parkville, Australia
 Parkville, Victoria Australia
 Site #001

Austria

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00785785**
 Contact: Novartis Pharmaceuticals
 +1-800-340-6843

Universitätsklinik f. Innere Medizin Onkologische Ambulanz
 Innsbruck, Austria
 Annaliese Gächter
 +43 512 504 23333
 annaliese.gaechter@uki.at
 Eisterer Wolfgang, MD

Universitätsklinik f. Innere Medizin I
 Vienna, Austria
 Thomas Brodowicz, MD
 +43-40400-4466
 +43-40400-4685
 Thomas Brodowicz, MD

Brazil

Nilotinib or Imatinib

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00751036**
 Contact: Novartis US: 1-800-340-6843

Site name unknown Barretos
 Barretos, Brazil

Site name unknown Belo Horizonte
 Belo Horizonte, Brazil

Site name unknown Jatal
 Jatal, Brazil

Site name unknown Jau
 Jau, Brazil

Site name unknown Porto Alegre
 Porto Alegre, Brazil

Site name unknown Rio de Janeiro
 Rio de Janeiro, Brazil

Site name unknown Santo Andre
 Santo Andre, Brazil

Canada

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: [NCT00785785](#)
 Contact: Novartis Pharmaceuticals
 +1-800-340-6843

Hotel Dieu du Quebec

Quebec, Canada
 Ann Wright
 1-418-691-2950
 Felix Couture, MD
 1-418-691-5225
 Felix Couture, MD

Mount Sinai Hospital

Toronto, ON Canada
 Martin Blackstein, MD
 011-416-586-5371
 Martin Blackstein, MD

Ottawa Regional Cancer Center University of Ottawa

Ottawa, Ontario Canada
 Caroline Proulx, MD
 613-737-7700 ext 70316
 Tim Asmis, MD

Maisonneuve-Rosemont Hospital

Montreal, QC Canada
 Jacinthe Lasalle, MD
 514-252-3400 ext 4670
 Lucas Sideris, MD

CHUM - Hopital Notre-Dame

Montreal, Quebec Canada
 Chantal Gosselin
 514-890-8000 ext. 24892
 Denis Soulieres, MD

CHUS - Hospital Fleurimont

Sherbrooke, Quebec
 Canada
 Brigitte Jean
 1-819-346-1110 ext.
 12872
 Rami Kotb, MD

BGT226

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: mTOR inhibitor
 PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #: [NCT00600275](#)
 Contact: Novartis
 800 340-6843

Princess Margaret Hospital

Toronto, ON Canada
 Lillian Siu, M.D.

Colombia

Nilotinib or Imatinib

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: [NCT00751036](#)
 Contact: Novartis US: 1-800-340-6843

**Site name unknown
 Medellin**
 Medellin, Colombia

**Site name unknown
 Monteria**
 Monteria, Colombia

Finland

Dasatinib (BMS-354825)

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Phase: 2
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFRα inhibitor + SRC inhibitor
 Strategy: Block KIT + Block KIT Signal Path
 NCT #: **NCT00568750**
 Contact: See site contact info below

Helsinki University Central Hospital
 Helsinki, Finland
 Mia Viskari,
 +358-9-4711,
 mia.viskari@hus.fi
 also 358-947-173-200
 Heikki Joensuu, MD

Radiation

Radiation Therapy as Palliative Treatment of GIST (GIST-RT)

Phase: 1
 Stage: Palliative
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: None
 Strategy: Radiation
 NCT #: **NCT00515931**
 Contact: See site contact info below

Helsinki University Central Hospital
 Helsinki, Finland
 947173208 Ext. 358
 heikki.joensuu@hus.fi
 Heikki Joensuu, MD

France

Imatinib

Prospective Multicentric Randomized Study of Gleevec® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFRα inhibitor
 Strategy: Block KIT
 NCT #: **NCT00367861**
 Contact: Jean Yves Blay, M.D, Ph.D

33607507064
blay@lyon.fnclcc.fr
Centre Oscar Lambret - Bordeaux
 Bordeaux, France
 Antoine Adenis, MD

Institut Bergonie
 Bordeaux, France
 Binh Bui Nguyen, MD

Centre Leon Berard
 Lyon, France
 +33607507064
blay@lyon.fnclcc.fr
 Jean Yves-Blay, MD, PhD

Hopital Edouard Herriot
 Lyon, France
 Jean-Yves Blay, MD, PhD

Hospital de La Timone
 Marseille, France
 Florence Duffaud, MD,
 PhD

Institut Paoli Calmette
 Marseilles, France
 Patrice Viens, MD, PhD

Centre Alexis Vautrin
 Nancy, France
 Maria Rios, MD

Institut Gustave-Roussy
 Villejuif Cedex, France
 Jean-Yves Blay

Masitinib, (AB1010)

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFRα inhibitor
 Strategy: Block KIT
 NCT #: **NCT00812240**
 Contact: Centre Oscar Lambret
 Antoine Adenis, M.D.
a-adenis@o-lambret.fr
 +33 (0)3 20 29 59 59

Hopital Jean Minjot
 Besancon, France

Institut Bergonie
 Bordeaux, France
 Binh Bui Nguyen, MD

Centre Georges Francois Leclerc
 Dijon, France

Centre Hospitalier Victor Jousset
 Dreux, France

Centre Oscar Lambret - Lille
 Lille, France
 Antoine Adenis, MD

Centre Leon Berard
 Lyon, France
 +33607507064
blay@lyon.fnclcc.fr
 Jean Yves-Blay, MD, PhD

Institut Paoli Calmette
 Marseilles, France
 Patrice Viens, MD, PhD

Centre Val d'Aurele
 Montpellier, France

Centre Rene Gauducheau
 Nantes, France

Hopital de la Source
 Orleans, France

**Hopital European
Georges Pompidou**
Paris, France

Hopital Robert Debre
Reims, France

Hopital Charles Nicolle
Rouen, France

Centre Rene Huguenin
Saint-Cloud, France

Dasatinib (BMS-354825)
*Dasatinib as First-Line Therapy in
Treating Patients With Gastrointestinal
Stromal Tumors*

Phase: 2
Stage: First-line
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: KIT/PDGFR inhibitor +
SRC inhibitor
Strategy: Block KIT + Block KIT
Signal Path
NCT #: **NCT00568750**
Contact: See site contact info below

Institut Bergonie
Bordeaux, France
33-5-56-33-3212
Binh Bui Nguyen, MD

**Hopital Edouard
Herriot**
Lyon, France
33-4-72-11-7398
Jean-Yves Blay, MD, PhD

Centre Paul Strauss
Strasbourg, France
33-3-88-252-401

**Institut Gustave-
Roussy**
Villejuif Cedex, France
33-1-42-114-316
Jean-Yves Blay

Imatinib + IL-2
Imatinib + IL-2

Phase: 1
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: KIT inhibitor + Immune
stimulate
Strategy: Block KIT + Stimulate the
immune system
NCT #:
Contact: See site contact info below

**Institut Gustave-
Roussy**
Villejuif Cedex, France
Patricia Pautier, MD
33 (0) 1 42 11 42 11
pautier@igr.fr
Laurence Zitvogel, MD

GDC-0980
*A Study Evaluating GDC-0980
Administered Once Weekly in Patients
With Refractory Solid Tumors or Non-
Hodgkin's Lymphoma*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: PI3K inhibitor + mTOR
inhibitor
Strategy: Block KIT Signal Path
NCT #: **NCT00854126**
Contact: Mick O'Quigley
oquigley.michael@gene.com

**Institut Gustave-
Roussy**
Villejuif Cedex, France

HSP990
*A Study of HSP990 Administered by
Mouth in Adult Patients With Advanced
Solid Tumors*

Phase: 1
Stage: Gleevec-resistant
Conditions: Solid Tumors
Drug Type: HSP90 inhibitor
Strategy: Destroy KIT
NCT #: **NCT00879905**
Contact: Novartis Pharmaceuticals
+1-800-340-6843
+1-800-340-6843

**Institut Claudius
Regaud**
Toulouse, France

Nilotinib or Imatinib
*Phase III, Open-Label Study of Nilotinib
Versus Imatinib in GIST Patients*

Phase: 3
Stage: First-line
Conditions: Gastrointestinal Stromal
Tumor
Drug Type: KIT/PDGFR inhibitor
Strategy: Block KIT
NCT #: **NCT00785785**
Contact: Novartis Pharmaceuticals
+1-800-340-6843

Centre Leon Berard
Lyon, France
+33-4-78-58-27-57
blay@lyon.fnclcc.fr
Jean Yves-Blay, MD, PhD

**Institut Gustave-
Roussy**
Villejuif Cedex, France
+33-1-42-11-43-05
axel.lecesne@igr.fr
Axel Le Cesne, MD

Germany

Dasatinib (BMS-354825)

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Phase: 2
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor + SRC inhibitor
 Strategy: Block KIT + Block KIT Signal Path
 NCT #: **NCT00568750**
 Contact: See site contact info below
Universitätsklinikum Essen, West Germany Cancer Center
 Essen, Germany
 49-201-723-85-011

Nilotinib

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)

Phase: 2
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00756509**
 Contact: Novartis Basel
 + 41 61 324 1111
 +1-800-340-6843
Site name unknown, Bad Saarow
 Bad Saarow, Germany

Everolimus

Treatment of Patients With RAD001 Who Have Progressive Sarcoma

Phase: 2
 Stage: Gleevec-resistant
 Conditions: Sarcoma
 Drug Type: mTOR inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00767819**
 Contact: Novartis Pharmaceuticals
 +1 800-340-6843
Site name unknown, Berlin
 Berlin, Germany
Site name unknown, Dusseldorf
 Dusseldorf, Germany
Site name unknown, Mannheim 68135
 Mannheim, Germany

Site name unknown, Munchen
 Munchen, Germany

Multi-bacteria vaccine (MBV)

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: Immune stimulate
 Strategy: Stimulate the immune system
 NCT #: **NCT00623831**
 Contact: See site contact info below
Krankenhaus Nordwest
 Frankfurt, Germany
 Antje Neumann
 neumann.antje@khnw.de
 069 7601 4161
 Elke Jaeger, MD

India

Sunitinib

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00094029**
 Contact: Pfizer Oncology Clinical Trial Information Service
 1-877-369-9753

Site name unknown Delhi
 New Delhi, Delhi India

Site name unknown Mumbai
 Mumbai, Mumbai India

Israel

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00785785**
 Contact: Novartis Pharmaceuticals
 +1-800-340-6843

Sheba Medical Center
 Rahat, Israel
 Hila Chaimovitch
 +972-3-5302191
 hilla.attal@sheba.health.gov.il

Ido Wolf, M.D.

Nilotinib

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinase (TK) Inhibitor

Phase: 2
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00633295**
 Contact: Novartis Basel
 41 61 324 1111

Site name unknown, Jerusalem
 Jerusalem, Israel

Site name unknown, Tel Aviv
 Tel Aviv, Israel

Site name unknown, Tel Hashomer
 Tel Hashomer, Israel

Italy

Nilotinib

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)

Phase: 2
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00756509**
 Contact: Novartis Basel
 + 41 61 324 1111
 +1-800-340-6843

Site name unknown, Milan
 Milan, Italy

Everolimus

Treatment of Patients With RAD001 Who Have Progressive Sarcoma

Phase: 2
 Stage: Gleevec-resistant
 Conditions: Sarcoma
 Drug Type: mTOR inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00767819**
 Contact: Novartis Pharmaceuticals
 +1 800-340-6843

Site name unknown, Milan
 Milan, Italy

Japan

Imatinib

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Phase: 2
 Stage: All
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00764595**
 Contact: See site contact info below

Niigata University Medical and Dental School
 Niigata, Japan
 81-25-227-2228
 Tatsuo Kanda, MD

Surgery

Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Phase: 2
 Stage: All
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: Surgery
 Strategy: Surgery
 NCT #: **NCT00769782**
 Contact: See site contact info below

Niigata University Medical and Dental School
 Niigata, Japan
 81-25-227-2228
 Tatsuo Kanda, MD

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00785785**
 Contact: Novartis Pharmaceuticals
 +1-800-340-6843

Aichi Cancer Center Hospital

Aichi, Japan
 Akira Sawaki, MD
 +81-52-762-6111
 jutaku_a@aichi-cc.jp
 Akira Sawaki, MD

National Cancer Center Hospital East

Chiba, Japan
 Toshihiko Doi, MD
 +81-4-7133-1111
 tdoi@east.ncc.go.jp
 Toshihiko Doi, MD

Kyushu University Hospital

Fukuoka City, Japan
 +81-92-641-1151
 kakegi@surg2.med.kyushu-u.ac.jp
 Yoshihiro Kakeji, MD

Hokkaido University Hospital

Hokkaido, Japan
 Yoshito Komatsu
 +81-11-706-5657
 Yoshito Komatsu, MD

Kanagawa Cancer Center

Kanagawa, Japan
 Haruhiko Cho, MD
 +81-45-391-5791
 Haruhiko Cho, MD

Kumamoto University Hospital

Kumamoto, Japan
 Hideo Baba, MD
 +81-96-344-2111
 hdebaba@kumamoto-u.ac.jp
 Hideo Baba, MD

Tohoku University Hospital

Miyagi, Japan
 Chikashi Ishioka, MD

Chikashi Ishioka, MD

Niigata University Medical and Dental School

Niigata, Japan
 Tatsuo Kanda, MD
 +81-25-227-0372
 kandat@med.niigata-u.ac.jp
 Tatsuo Kanda, MD

Kawasaki Medical School Hospital

Okayama, Japan
 Toshihiro Hirai, MD
 +81 86 462 1111

Toshihiro Hirai, MD

National Hospital Organization - Osaka General Hospital

Osaka, Japan
 Toshimasa Tsujinaka, MD
 +81 6 6942 1331
 toshi@onh.go.jp
 Toshimasa Tsujinaka, MD

Osaka University Hospital

Osaka, Japan
 Toshiro Nishida, MD
 +81-6-6879-5111
 toshin@surg1.med.osaka-u.ac.jp
 Toshiro Nishida, MD

Shizuoka Cancer Center

Shizuoka, Japan
 Yusuke Onozawa
 +81-55-989-5222
 y.onozawa@scchr.jp
 Yusuke Onozawa, MD

National Cancer Center Hospital

Tokyo, Japan
 Yasuhide Yamada, MD
 +81 33 542 5111
 yayamada@ncc.go.jp
 Yasuhide Yamada, MD

Lebanon

Masitinib, (AB1010)

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00812240**
 Contact: Centre Oscar Lambret
 Antoine Adenis, M.D.
 a-adenis@o-lambret.fr
 +33 (0)3 20 29 59 59

Hopital Saint-Georges Beirut, Lebanon

American University Hospital Beirut, Lebanon

Middle East Institute of Health Bsalim, Lebanon

Hopital Saint-Joseph Dora, Lebanon

Hamoud Hospital Saidia, Lebanon

Netherlands

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: [NCT00785785](#)
 Contact: Novartis Pharmaceuticals
 +1-800-340-6843

Leiden University
 Leiden, Netherlands
 Jan Ouwerkerk
 +31 71-5261965
 j.ouwerkerk@lumc.nl
 A. J. Gelderblom, MD

Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

Phase: 4
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: VEGFR inhibitor (TKI)
 Strategy: Block tumor blood vessel growth
 NCT #: [NCT00777504](#)
 Contact: See site contact info below

University Medical Center Nijmegen st Raboud
 Nijmegen, Gelderland
 Netherlands
 31 24 3610353
 c.vanherpen@onco.umcn.nl

C.M.L van Herpen, Md,
 Phd

Sunitinib or Sorafenib

Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or Gastrointestinal Stromal Tumor (GIST)

Phase:
 Stage: Palliative
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor + SRC inhibitor
 Strategy: Block KIT + Block related tumor signal paths
 NCT #: [NCT00979329](#)
 Contact: C.M.L. van Herpen, Md,
 Phd

31 24 3610353
 c.vanherpen@onco.umcn.nl
 S. Mulders, Md
 31 24 3610353
University Medical Center Nijmegen st Raboud
 Nijmegen, Gelderland
 Netherlands
 c.vanherpen@onco.umcn.nl
 C.M.L van Herpen, Md,
 Phd

Imatinib

A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.

Phase: 3
 Stage: Stable Disease
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #:
 Contact: Anne Kirkpatrick
 Project Manager - EORTC,
 Brussels, Belgium
 anne.kirkpatrick@eortc.be
 +32 2 7741691

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
 Amsterdam, Netherlands

New Zealand

Imatinib, Nilotinib

REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response

Phase: 2
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #:
 Contact: Karen Bracken
 02 9562 5071
 registerstudy@ctc.usyd.edu.au
 karen.bracken@ctc.usyd.edu.au

Christchurch Hospital
 Christchurch, New Zealand
 David Gibbs, MD

Palmerston North Hospital
 Palmerston North, New Zealand
 Garry Forgeson, MD

Panama

Nilotinib or Imatinib

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00751036**
 Contact: Novartis US: 1-800-340-6843

Site name unknown
Panama
 Panama, Panama

Republic of Korea

Nilotinib or Imatinib

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00751036**
 Contact: Novartis US: 1-800-340-6843

Site name unknown
Daegu
 Daegu, Republic of Korea

Site name unknown
Hwasun-gun
 Hwasun-gun, Republic of Korea

Site name unknown
Seoul
 Seoul, Republic of Korea

Nilotinib

Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST)

Phase:
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00976612**
 Contact: Yoon-Koo Kang, MD, PhD
 82-2-3010-3230
 ykkang@amc.seoul.kr
 Min-Hee Ryu, MD, PhD
 82-2-3010-5935
 miniryu@amc.seoul.kr
Asan Medical centre
 Seoul, Republic of Korea
 Yoon-Koo Kang, MD, PhD
 82-2-3010-3230
 ykkang@amc.seoul.kr
 Min-Hee Ryu, MD, PhD
 82-2-3010-5935
 miniryu@amc.seoul.kr

Spain

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00785785**
 Contact: Novartis Pharmaceuticals
 +1-800-340-6843

Consorci Hospitalari Parc Tauli

Barcelona, Spain
 Jose G. Ruiz
 +34-937-242-579
 jgarciar@tauli.cat
 Charles Pericay, MD

University Hospital La Paz

Madrid, Spain
 Cristobal Belda-Iniesta, MD
 34-1-2071138
 cbelda.hulp@salud.madrid.org
 Cristobal Belda-Iniesta, MD

BGT226

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: mTOR inhibitor
 PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00600275**
 Contact: Novartis
 800 340-6843

Hospital Vall d'Hebron
 Barcelona, Spain

XL147

Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00486135**
 Contact: Exelixis Contact Line
 866-939-4041

Hospital Vall d'Hebron

Barcelona, Spain
 Gemma Sala
 +34 93 489 4158
 gsala@vhebron.net
 Jose Baselga, MD, PhD

XL765

Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: mTOR inhibitor
 PI3K inhibitor
 Strategy: Block related tumor signal paths
 NCT #: **NCT00485719**
 Contact: Exelixis Contact Line
 866-939-4041

Hospital Vall d'Hebron

Barcelona, Spain
 Gemma Sala +34 93
 489 4158
 gsala@vhebron.net
 Jose Baselga, MD, PhD

Switzerland

Dasatinib (BMS-354825)

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Phase: 2
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor + SRC inhibitor
 Strategy: Block KIT + Block KIT Signal Path
 NCT #: **NCT00568750**
 Contact: See site contact info below

Kantonsspital Baden

Baden, Switzerland
 41-56-486-2511

Universitaetsspital-Basel

Basel, Switzerland
 41-61-265-5714

Saint Claraspital

Basel, Switzerland
 41-61-685-8325

Kantonsspital Bruderholz

Bruderholz, Switzerland
 41-61-436-3636

Kantonsspital Graubuenden

Chur, Switzerland
 41-21-314-0150

Hopital Cantonal Universitaire de Geneve

Geneva, Switzerland
 41-22-372-7744

Centre Hospitaleir Universitaire Vaudois

Lausanne, Switzerland
 41-21-314-0150
 Michael Montemurro, MD

Kantonsspital Liestal

Liestal, Switzerland
 41-61-925-2715

Kantonsspital - St Gallen

St. Gallen, Switzerland
 41-71-494-3569

City Hospital Triemli

Zurich, Switzerland
 41-44-466-1273

Onkozentrum - Klinik im Park

Zurich, Switzerland
 41-43-344-3333

UniversitaetsSpital Zuerich

Zurich, Switzerland
 41-44-255-2244

AUY922

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: HSP90 inhibitor
 Strategy: Destroy KIT
 NCT #: **NCT00526045**
 Contact: Novartis Pharmaceuticals
 1 800 340-6843

Site Name unknown, Bellinzona

Bellinzona, Switzerland

Thailand

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00785785**
 Contact: Novartis Pharmaceuticals
 +1-800-340-6843

Chulalongkorn University

Bangkok, Thailand
 Virote Sriuranpong, MD
 +66-2-256-4533
 vsmtcu40@gmail.com
 Virote Sriuranpong, MD

Siriraj Hospital

Bangkok, Thailand
 Vichien Srimuninnimit, MD
 +66-2-419-4488
 vsrimuninnimit@gmail.com

Vichien Srimuninnimit, MD

Prince of Songkla University

Songkla, Thailand
 Patrapim Sunpaweravong, MD
 +66-74-451-469
 spatrapi@medicine.psu.ac.th
 Patrapim Sunpaweravong, MD

UK

Nilotinib or Imatinib

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00751036**
 Contact: Novartis US: 1-800-340-6843

Site name unknown Bangkok
 Bangkok, Thailand

Khon Kaen University
 Khon Kaen, Thailand

Prince of Songkla University
 Songkla, Thailand

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
 Stage: First-line
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: **NCT00785785**
 Contact: Novartis Pharmaceuticals +1-800-340-6843

Freeman Hospital - Northern Centre for Cancer Care
 Newcastle,, UK
 Jonathan Stoddart
 0191 213 8438
 jonathan.stoddart@nuth.nhs.uk
 Mark Verrill, M.D.

GDC-0980

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor + mTOR inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00854152**
 Contact: Mick O'Quigley
 oquigley.michael@gene.com

Department of Cancer Therapeutics, Institute of Cancer Research
 Sutton, Surrey UK

GDC-0980

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor + mTOR inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00854126**
 Contact: Mick O'Quigley
 oquigley.michael@gene.com

Christie Hospital NHS Trust
 Manchester, Lancashire UK

GDC-0941

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: PI3K inhibitor
 Strategy: Block KIT Signal Path
 NCT #: **NCT00876122**
 Contact: See site contact info below

Royal Marsden Hospital
 London, UK
 Krunal Shah
 0208 722 4005
 Krunal.Shah@icr.ac.uk

OSI-906

Phase 1 Study of Continuous OSI-906 Dosing

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: [NCT00514007](#)
 Contact: OSIP Medical Information
 800.572.1932, x7821
 medical-information@osip.com
Beatson West of Scotland Cancer Centre
 Glasgow, UK

OSI-906

Phase 1 Study of Intermittent OSI-906 Dosing

Phase: 1
 Stage: Gleevec-resistant
 Conditions: Solid Tumors
 Drug Type: IGF1R inhibitor
 Strategy: Block related tumor signal paths
 NCT #: [NCT00514306](#)
 Contact: OSIP Medical Information
 800.572.1932 ext 7821
 medical-information@osip.com
Department of Cancer Therapeutics, Institute of Cancer Research
 Sutton, Surrey UK

Venezuela

Nilotinib or Imatinib

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: [NCT00751036](#)
 Contact: Novartis US: 1-800-340-6843

Site name unknown
Caracas
 Caracas, Venezuela

Sunitinib

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Phase: 3
 Stage: Gleevec-resistant
 Conditions: Gastrointestinal Stromal Tumor
 Drug Type: KIT/PDGFR inhibitor
 Strategy: Block KIT
 NCT #: [NCT00094029](#)
 Contact: Pfizer Oncology Clinical Trial Information Service
 1-877-369-9753